Literature DB >> 15661031

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

Jessica M Lindvall1, K Emelie M Blomberg, Jouni Väliaho, Leonardo Vargas, Juhana E Heinonen, Anna Berglöf, Abdalla J Mohamed, Beston F Nore, Mauno Vihinen, C I Edvard Smith.   

Abstract

Bruton's tyrosine kinase (Btk) is encoded by the gene that when mutated causes the primary immunodeficiency disease X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice. Btk is a member of the Tec family of protein tyrosine kinases (PTKs) and plays a vital, but diverse, modulatory role in many cellular processes. Mutations affecting Btk block B-lymphocyte development. Btk is conserved among species, and in this review, we present the sequence of the full-length rat Btk and find it to be analogous to the mouse Btk sequence. We have also analyzed the wealth of information compiled in the mutation database for XLA (BTKbase), representing 554 unique molecular events in 823 families and demonstrate that only selected amino acids are sensitive to replacement (P < 0.001). Although genotype-phenotype correlations have not been established in XLA, based on these findings, we hypothesize that this relationship indeed exists. Using short interfering-RNA technology, we have previously generated active constructs downregulating Btk expression. However, application of recently established guidelines to enhance or decrease the activity was not successful, demonstrating the importance of the primary sequence. We also review the outcome of expression profiling, comparing B lymphocytes from XLA-, Xid-, and Btk-knockout (KO) donors to healthy controls. Finally, in spite of a few genes differing in expression between Xid- and Btk-KO mice, in vivo competition between cells expressing either mutation shows that there is no selective survival advantage of cells carrying one genetic defect over the other. We conclusively demonstrate that for the R28C-missense mutant (Xid), there is no biologically relevant residual activity or any dominant negative effect versus other proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661031     DOI: 10.1111/j.0105-2896.2005.00225.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  56 in total

1.  Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Authors:  Li Ren; Amanda Campbell; Huiqing Fang; Shalini Gautam; Saranya Elavazhagan; Kavin Fatehchand; Payal Mehta; Andrew Stiff; Brenda F Reader; Xiaokui Mo; John C Byrd; William E Carson; Jonathan P Butchar; Susheela Tridandapani
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 2.  RNA interference in biology and disease.

Authors:  Carol A Sledz; Bryan R G Williams
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

3.  Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

Authors:  Andreas Kuglstatter; April Wong; Stan Tsing; Simon W Lee; Yan Lou; Armando G Villaseñor; J Michael Bradshaw; David Shaw; Jim W Barnett; Michelle F Browner
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

4.  Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice.

Authors:  Maroof Hasan; Gabriela Lopez-Herrera; K Emelie M Blomberg; Jessica M Lindvall; Anna Berglöf; C I Edvard Smith; Leonardo Vargas
Journal:  Immunology       Date:  2007-08-28       Impact factor: 7.397

5.  The calcium channel mucolipin-3 is a novel regulator of trafficking along the endosomal pathway.

Authors:  Jose A Martina; Benjamin Lelouvier; Rosa Puertollano
Journal:  Traffic       Date:  2009-04-29       Impact factor: 6.215

Review 6.  Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis.

Authors:  Marc Tebruegge; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 7.  Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease.

Authors:  P C Dubois; D A van Heel
Journal:  Clin Exp Immunol       Date:  2008-08       Impact factor: 4.330

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 9.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

10.  Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.

Authors:  Pamela P W Lee; Tong-Xin Chen; Li-Ping Jiang; Koon-Wing Chan; Wanling Yang; Bee-Wah Lee; Wen-Chin Chiang; Xiang-Yuan Chen; Susanna F S Fok; Tsz-Leung Lee; Marco H K Ho; Xi-Qiang Yang; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2009-11-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.